Precision Medicine and Care Decisions
A confirmed inherited variant does more than name a risk — it can reshape screening schedules, open risk-reducing options, and in some cancers guide targeted therapy. Here is how genomic findings translate into individualized care, and where honest uncertainty still belongs in the conversation.
Precision Medicine
What a genetic result actually changes
Precision medicine is the practice of tailoring prevention, surveillance, and treatment to an individual's biology rather than to population averages. In hereditary cancer, the biological input is often a pathogenic or likely-pathogenic variant in a gene such as BRCA1, BRCA2, PALB2, or one of the Lynch syndrome mismatch-repair genes.
Knowing that variant is present shifts a person's estimated lifetime risk away from the general-population baseline. That shifted estimate is what clinicians use to decide how early surveillance should begin, how often it should repeat, which imaging modalities add value, and whether risk-reducing surgery or medication is a reasonable option to discuss. The variant does not dictate a single course of action — it changes the menu of choices and the math behind them.
How a genomic finding informs care
The path from a sequenced sample to a care decision moves through several distinct stages, each one adding context rather than certainty.
Confirm and classify the variant
The first question is not 'what do we do' but 'how confident are we.' A variant is classified as pathogenic, likely pathogenic, of uncertain significance (VUS), likely benign, or benign. Only pathogenic and likely-pathogenic findings should drive management; a VUS is generally not acted upon until further evidence reclassifies it.
Estimate risk in context
A confirmed variant is interpreted alongside personal and family history, age, and any prior diagnoses. The same gene can carry different practical implications depending on which specific variant it is and the rest of a person's clinical picture, so risk is estimated for the individual, not assumed from the gene name alone.
Adjust the surveillance schedule
Higher estimated risk typically means earlier and more frequent screening, and sometimes additional modalities — for example, breast MRI added to mammography for certain variants, or earlier and more frequent colonoscopy in Lynch syndrome. The aim is to detect disease earlier, when intervention tends to be more effective.
Weigh risk-reducing options
Depending on the variant, options may include risk-reducing medication or surgery. These are discussed as choices with trade-offs — benefits, side effects, timing, and personal values all matter — not as automatic prescriptions handed down from a test result.
Consider targeted and informed therapy
When cancer is present, germline and tumor genomic data can sometimes point toward therapies matched to the underlying biology — for instance, PARP inhibitors in certain BRCA-associated cancers, or immunotherapy considerations in mismatch-repair-deficient tumors. Eligibility depends on the specific clinical situation and is determined by the treating oncology team.
Decide together, and revisit
Shared decision-making puts the evidence in front of the patient and folds in their priorities. Because variant classifications and guidelines evolve, plans are revisited over time — a VUS may be reclassified, and recommendations may be refined as more data accumulates.
Longitudinal data sharpens the recommendations
Many management recommendations rest on outcome data gathered over years from people who carry the same variants. Multi-institutional registries — the kind that prospectively follow patients after multi-gene panel testing — are how the field learns which variants carry which real-world risks, and how interventions actually perform over time.
That longitudinal evidence is especially valuable for the harder cases: rarer genes, variants of uncertain significance awaiting reclassification, and the moderate-penetrance findings where the right surveillance interval is still being calibrated. As registry data grows, estimates become more precise and recommendations less reliant on extrapolation. Precision medicine, in other words, gets more precise as the dataset behind it matures.
Frequently asked questions
Does a positive genetic result mean I will get cancer?
No. A pathogenic variant raises estimated risk relative to the general population, but it is a probability, not a certainty. Many carriers never develop the associated cancer, and the degree of increased risk varies by gene, by the specific variant, and by personal and family context. The result informs how closely you are monitored — it does not deliver a diagnosis.
What is a variant of uncertain significance, and should it change my care?
A variant of uncertain significance (VUS) is a genetic change whose effect on disease risk is not yet established. Current guidance is that a VUS should generally not drive medical decisions on its own. It may be reclassified — as benign or as pathogenic — as more evidence accumulates, which is one reason periodic follow-up with a genetics provider is useful.
How does an inherited variant lead to a targeted therapy?
Some therapies are designed around specific biological vulnerabilities. When a tumor or a person's germline carries a particular variant, that biology can sometimes match an approved targeted treatment — PARP inhibitors in certain BRCA-associated cancers are a frequently cited example. Whether any given therapy applies is a clinical determination made by the treating team based on the full diagnostic picture, not by the genetic result in isolation.
Who helps me interpret what my results mean for my care?
Genetic counselors and clinicians trained in cancer genetics interpret results in context, explain the level of certainty, and lay out the options. Shared decision-making means the evidence and the trade-offs are discussed openly so the plan reflects both the science and your own priorities. This page is educational reference material and is not a substitute for that individualized guidance.
Genomic data is a starting point, not a verdict
Understanding how an inherited variant maps to screening, prevention, and treatment options helps you ask better questions and make decisions that fit your situation. If you have questions about the concepts on this page, reach out — we are glad to point you toward credible, plain-language explanations.